![Po Wen Wu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Po Wen Wu
Vorstandsvorsitzender bei
Polaris Pharmaceuticals, Inc.
Profil
Po Wen Wu is currently the President & Chief Executive Officer at Polaris Pharmaceuticals, Inc. and the Chairman & Chief Executive Officer at Designerx Pharmaceuticals, Inc. He is also the Chief Executive Officer & Director at DRX USA, DRX Chengdu, and TDW Pharmaceuticals, Inc. Additionally, he serves as a Director at DesigneRx Europe Ltd., DRX SHANGHAI, and DRX Hong Kong.
In the past, he was the President & Chief Executive Officer at Polaris Group, Inc. from 2011 to 2013 and the Chairman & General Manager at Polaris Group.
Dr. Wu holds a doctorate degree from the University of California, Berkeley.
Aktive Positionen von Po Wen Wu
| Unternehmen | Position | Beginn |
|---|---|---|
Polaris Pharmaceuticals, Inc.
 Polaris Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Researches and develops protein drugs for cancer treatment | Vorstandsvorsitzender | - |
DesigneRx Europe Ltd. | Direktor/Vorstandsmitglied | - |
Designerx Pharmaceuticals, Inc.
 Designerx Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Part of Polaris Group, Designerx Pharmaceuticals, Inc. is a multinational biotechnology company that specializes in the development of novel anti-cancer therapies. The company is based in Vacaville, CA. The company's lead drug candidate, Pegargiminase (Adi-Peg 20), is a biologic in late-stage clinical development for a variety of cancers. The CEO of the company is Po Wen Wu. | Vorstandsvorsitzender | - |
DRX USA | Vorstandsvorsitzender | - |
TDW Pharmaceuticals, Inc. | Vorstandsvorsitzender | - |
DRX Chengdu | Vorstandsvorsitzender | - |
DRX SHANGHAI | Direktor/Vorstandsmitglied | - |
DRX Hong Kong | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Po Wen Wu
| Unternehmen | Position | Ende |
|---|---|---|
Polaris Group, Inc.
 Polaris Group, Inc. Real Estate DevelopmentFinance Offers real estate sales, marketing & consulting services | Präsident | 06.03.2013 |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Po Wen Wu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Polaris Group, Inc.
Polaris Group, Inc. Real Estate DevelopmentFinance Offers real estate sales, marketing & consulting services | Finance |
Polaris Pharmaceuticals, Inc.
Polaris Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Researches and develops protein drugs for cancer treatment | Health Technology |
TDW Pharmaceuticals, Inc. | |
Polaris Group
 Polaris Group BiotechnologyHealth Technology Engages in research and development of protein drugs to treat cancer and other debilitating diseases in humans | Health Technology |
DesigneRx Europe Ltd. | |
Designerx Pharmaceuticals, Inc.
Designerx Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Part of Polaris Group, Designerx Pharmaceuticals, Inc. is a multinational biotechnology company that specializes in the development of novel anti-cancer therapies. The company is based in Vacaville, CA. The company's lead drug candidate, Pegargiminase (Adi-Peg 20), is a biologic in late-stage clinical development for a variety of cancers. The CEO of the company is Po Wen Wu. | Health Technology |
DRX USA | |
DRX Chengdu | |
DRX SHANGHAI | |
DRX Hong Kong |
